Off-label use of Amplatzer Duct Occluder II additional sizes.

J Cardiovasc Med (Hagerstown)

Paediatric Cardiology, A.O.R.N. 'Ospedali dei Colli', 2nd University of Naples, Naples, Italy.

Published: June 2017

Objective: To report our experience on novel, off-label use of Amplatzer Duct Occluder type II additional sizes (ADO II-AS) device (St. Jude Medical, Inc.; St. Paul, Minnesota, USA) to manage nonduct shunt lesions.

Methods And Results: Among the 114 patients submitted to ADO II-AS implantation at our institution, 12 received this device as off-label treatment of paravalvular leak (n = 5), sinus of Valsalva fissuration (n = 2), accessory atrial septal defect (n = 2), muscular ventricular septal defect (n = 1), bleeding bronchial artery aneurysm (n = 1) and reverse shunt due to abnormal origin of left subclavian artery from pulmonary artery (n = 1). Age and body weight of these patients ranged from 3 to 74 years and from 15 to 80 kg, respectively. All procedures were completed without anatomical, functional or ECG complications and without residual shunt. In one patient with mitral paravalvular leak, mild restriction of the posterior disc excursion after device deployment was recorded.

Conclusion: In our case series, ADO II-AS was well tolerated, versatile and cost-effective in treatment of different types of nonduct shunt lesions, mainly in young children and in older patients with comorbidities.

Download full-text PDF

Source
http://dx.doi.org/10.2459/JCM.0000000000000491DOI Listing

Publication Analysis

Top Keywords

ado ii-as
12
off-label amplatzer
8
amplatzer duct
8
duct occluder
8
additional sizes
8
nonduct shunt
8
paravalvular leak
8
septal defect
8
occluder additional
4
sizes objective
4

Similar Publications

Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study.

BMC Cardiovasc Disord

January 2025

Cardio/Endo-metabolic and Microbiome Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, 360101, Nigeria.

Background: Hypertension is a major cause of cardiac dysfunction. The earliest manifestation is left ventricular remodeling/hypertrophy. The occurrence of adverse cardiac remodeling and outcomes occurs irrespective of age in blacks.

View Article and Find Full Text PDF
Article Synopsis
  • - This review discusses a phase II clinical trial that compared the effectiveness of adjuvant trastuzumab emtansine (T-DM1) with a combination of paclitaxel and trastuzumab (TH) for treating stage I HER2-positive breast cancer, as studied in the ATEMPT trial.
  • - Results showed that patients receiving T-DM1 experienced better disease-free survival, meaning they had a lower chance of cancer returning after treatment.
  • - However, the T-DM1 group also faced more treatment-related discontinuations and did not have fewer toxicities, indicating that further long-term follow-up is necessary to assess overall survival benefits between T-DM1 and TH.
View Article and Find Full Text PDF

Objective: This study describes 3-year follow-up of 200 infants weighing ≥ 700 grams who underwent transcatheter patent ductus arteriosus (PDA) closure with the Amplatzer Piccolo™ Occluder.

Study Design: Between June 2017 and February 2019, 200 children were enrolled in this U.S.

View Article and Find Full Text PDF

Objectives Transcatheter closure is the treatment of choice for most patent ductus arteriosus (PDA) in infants, children, and adults. However, there is a controversy regarding transcatheter closure of clinically silent PDAs. Some authors favor device closure to eliminate the lifelong risk of infective endarteritis while others recommend avoiding PDA closure in such patients.

View Article and Find Full Text PDF

Transcatheter closure of patent ductus arteriosus (PDA) in premature infants is a feasible, safe, and an effective alternative to surgical ligation and may be performed with an implant success rate of 97%. Major procedural complications related to transcatheter PDA closure in extremely low birth weight (ELBW) infants are relatively infrequent (< 3%) ,but may be associated with a fatality if not optimally managed. Operators performing transcatheter PDA closures should be knowledgeable about these potential complications and management options.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!